- Feb 8 at 6:00am ET
Add a producer of inhalable migraine headache treatments to its Botox and other products and you have a winning company.
- Jan 23 at 5:07pm ET
Cramer is bullish on Synovus, Unilever and Cree but urges caution on Map Pharmaceuticals and KB Homes.
- Dec 19 at 9:12am ET
A list of stocks with drugs expecting FDA decisions in 2013
- Nov 20 at 10:17am ET
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies
- Nov 14 at 9:14am ET
Why is it taking so long for FDA to respond to MAP Pharma's Levadex resubmission?
- Apr 13 at 6:00am ET
MAP Pharmaceuticals (Nasdaq:MAPP) has been downgraded by TheStreet Ratings from from a hold to sell.
- Apr 2 at 4:09am ET
MAP Pharmaceuticals (Nasdaq:MAPP) has been downgraded by TheStreet Ratings from from a buy to hold.
- Mar 30 at 5:30am ET
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
- Mar 26 at 4:15pm ET
FDA regulators have likely derailed MAP Pharma's plans to market an inhaled migraine drug known as Levadex.
- Mar 26 at 6:09am ET
MAP Pharmaceuticals (Nasdaq:MAPP) has been upgraded by TheStreet Ratings from a hold to buy.
